Drug Maker Named In Investor Suit Over Schizophrenia Drug Clinical Results
BOSTON — A biopharmaceutical company and its CEO violated federal securities laws by misrepresenting the success of Phase 2b clinical trial results for the drug maker’s schizophrenia treatment drug, as well...To view the full article, register now.
Already a subscriber? Click here to view full article